EDMONTON, April 13 /CNW/ - Compass Biotechnologies, Inc. (Compass) is
newly focused on the development and commercialization of generic,
biosimiliar and bio-better products. Generic drugs are chemical copies
of existing drugs and biosimiliars( biologics) are protein based drugs
that do a similar job to the original biological product. Bio-Better
products are new versions of patent-expired biologically based drugs
that do the job smarter, more economically, or with a better
side-effect profile. A "bio-better" is a biopharmaceutical product that
is a copy of an existing product but is designed to have superior
efficacy, safety, or improved drug delivery characteristics compared to
the original product.
As part of this new focus Compass is pleased to announce the launch of
its new website located at www.compassbio.net. The website designed by Mr. George Ptylik of AdWiz http://www.adwiz.biz/ enhances the message of the Company while ensuring that all relevant
and important information is delivered to our shareholders and the
public at large in a professional and consistent manner.
Mr. Likes CEO commented "the website gives the right tone for our
message and we will continue to update and expand the site with
informational links, articles, press releases and a newsletter as we
continue to evolve our franchise."
About Compass Biotechnologies
Compass Biotechnologies (COBI: OB) is an Edmonton based biotechnology
product development company focused on generic, biosimiliar and
biobetter products. From a development perspective, these types of
products have lower development costs and lower development risk due to
well established mechanisms of action, a known safety profile, with
broad clinical indications for physician use. Comparability testing in
preclinical and clinical trials will be needed to show the added
benefits of the biosimiliar and bio-better drug product.
Compass Biotechnologies also has an wholly owned subsidiary company
called C-Pharma Inc.
About C-Pharma www.c-pharma.net
Compass has also created a private wholly owned subsidiary company
called C- Pharma Inc. This Company through its parent Compass; is
charged with the creation of a Hepatitis product development
franchise. C-Pharma has acquired the rights to novel vaccine
technology which is currently being developed for Hepatitis C
applications. This technology was previously developed at the National
Institutes of Health (NIH) and licensed to the Company on a worldwide
exclusive basis. In addition C-Pharma is developing its own generics
for two drugs known as Ribavirin and pegylated alpha interferon. These
two drugs are currently the drugs used for patients who are chronically
infected with the Hepatitis C virus and in combination are the current
standard of care. These two drugs when used together for Hepatitis C
chronic infection create a market of $2 billion a year worldwide.
Forward Looking Statements
This news release contains "forward-looking statements", as that term is
defined in Section 27A of the United States Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in this
current report which are not purely historical are forward-looking
statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainty of financial estimates and projections, the competitive and
regulatory environments, stock market conditions, unforeseen technical
difficulties and our ongoing ability to operate a business and obtain
financing. These forward-looking statements are made as of the date of
this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking
statements. Although we believe that our beliefs, plans, expectations
and intentions contained in this current report are reasonable, there
can be no assurance that such beliefs, plans, expectations or
intentions will prove to be accurate. Investors should consult all of
the information set forth herein and should also refer to the risk
factors disclosure outlined in our quarterly reports on Form 10-Q and
our other periodic reports filed from time-to-time with the Securities
and Exchange Commission pursuant to the Securities Exchange Act.
SOURCE Compass Biotechnologies Inc.
For further information:
Compass Biotechnologies Inc.
Mr. Garth Likes